A Randomized Phase II Study of SUBATM-itraconazole in Patients With Untreated Squamous NSCLC.
Response rates.

Changes in tumor blood flow.
Non-small Cell Lung Cancer Metastatic
DRUG: Cisplatin + Gemcitabine with SUBATM-itraconazole|DRUG: Cisplatin + Gemcitabine
Objective Response Rates, Per response evaluation criteria in solid tumors criteria, 6 weeks|Tumor Blood Flow., To assess the changes in tumor blood flow as measured by contrast enhanced MRI scanning in patients with metastatic squamous non-small cell lung cancer treated with cisplatin and gemcitabine with or without SUBATM-itraconazole., 6 weeks.
Median Time to Progression, To determine the median time to progression and median duration of survival of patients with metastatic squamous non-small cell lung cancer treated with cisplatin and gemcitabine with or without SUBATM-itraconazole., 2 years.|Adverse Effects, To characterize the adverse effects of cisplatin and gemcitabine with or without SUBATM-itraconazole in this patient population., 2 years.|Itraconazole Exposure Parameters, To correlate itraconazole exposure parameters with median time to progression and median survival in this patient population., 2 years.|Tumor Necrosis, To assess changes in tumor necrosis in response to cisplatin and gemcitabine with or without SUBATM-itraconazole., 2 years.
To determine the objective response rates of cisplatin and gemcitabine with or without SUBATM-itraconazole in patients with chemotherapy-na√Øve metastatic squamous non-small cell lung cancer.

To assess the changes in tumor blood flow as measured by contrast enhanced MRI scanning in patients with metastatic squamous non-small cell lung cancer treated with cisplatin and gemcitabine with or without SUBATM-itraconazole.